Tom Marjot

@tom-marjot.bsky.social

Liver doctor. NIHR Academic Clinical Lecturer at University of Oxford. Interested in #MASLD, #circadian rhythms, & #sleep. #EASL YI Taskforce.

In these unprecedented dark times for American life science and medical research (no less well beyond biomedicine), my coping mechanism is to laser focus on the unremitting and remarkable daily advances, and the fervent hope these will not be slowed or interrupted.

Breakthroughs Beyond the Journal @jhepatology.bsky.social 🚨The liver is central to fructose-associated cancer ▶️Tumors cannot use fructose directly ▶️Liver converts to specific lipids (LPC) ▶️LPCs integrate into new cancer membranes Can this explain link between MASLD & extra-hepatic cancer?

Highlights from latest article in Breakthroughs Beyond the Journal in Journal of Hepatology. It showcases work published in Nature.

2025 is the perfect year to take your career to the next level🚀 There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force. Apply by 20 January: easl.eu/leadership25 #LiverSky

1: In 2025, look out for a new section in Journal of Hepatology: "Breakthroughs Beyond the Journal". Editorial-style analyses of pivotal liver research. #LiverSky 2: My comment on work from Cell Metabolism showing that MI drives #MASH. The interaction between these two conditions works BOTH ways👇

New evidence of cross-disease communication between heart and liver

Hello, #MedSky community! We’re excited to begin our Bluesky journey. Here is a sampling of the trusted, influential, and essential information you can expect when you follow us:

1/3 What happens when science and every day clinical practice comes together? A 🧵 You get a packed room with not even a place to stand 👇🏼 Why? I firmly believe that we need to bridge the gap between research and clinical application in our scientific meetings. #TLM24

Bild